Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/EEF2_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/EEF2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/EEF2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/EEF2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/EEF2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EEF2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EEF2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/EEF2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EEF2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/EEF2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EEF2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EEF2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00022444 | Prostate | BPH | hematopoietic progenitor cell differentiation | 34/3107 | 114/18723 | 3.08e-04 | 2.37e-03 | 34 |
GO:007124810 | Prostate | BPH | cellular response to metal ion | 52/3107 | 197/18723 | 3.13e-04 | 2.39e-03 | 52 |
GO:000641410 | Prostate | BPH | translational elongation | 20/3107 | 55/18723 | 3.18e-04 | 2.43e-03 | 20 |
GO:00030127 | Prostate | BPH | muscle system process | 103/3107 | 452/18723 | 3.54e-04 | 2.62e-03 | 103 |
GO:005159118 | Prostate | BPH | response to cAMP | 29/3107 | 93/18723 | 3.66e-04 | 2.71e-03 | 29 |
GO:00519623 | Prostate | BPH | positive regulation of nervous system development | 67/3107 | 272/18723 | 4.15e-04 | 3.01e-03 | 67 |
GO:00515928 | Prostate | BPH | response to calcium ion | 41/3107 | 149/18723 | 5.22e-04 | 3.68e-03 | 41 |
GO:00109762 | Prostate | BPH | positive regulation of neuron projection development | 44/3107 | 163/18723 | 5.23e-04 | 3.68e-03 | 44 |
GO:00609974 | Prostate | BPH | dendritic spine morphogenesis | 21/3107 | 61/18723 | 5.37e-04 | 3.77e-03 | 21 |
GO:00519604 | Prostate | BPH | regulation of nervous system development | 100/3107 | 443/18723 | 6.02e-04 | 4.16e-03 | 100 |
GO:00323558 | Prostate | BPH | response to estradiol | 38/3107 | 141/18723 | 1.25e-03 | 7.57e-03 | 38 |
GO:001407416 | Prostate | BPH | response to purine-containing compound | 39/3107 | 148/18723 | 1.71e-03 | 9.84e-03 | 39 |
GO:00609992 | Prostate | BPH | positive regulation of dendritic spine development | 15/3107 | 42/18723 | 2.14e-03 | 1.19e-02 | 15 |
GO:004668316 | Prostate | BPH | response to organophosphorus | 35/3107 | 131/18723 | 2.23e-03 | 1.23e-02 | 35 |
GO:00420634 | Prostate | BPH | gliogenesis | 68/3107 | 301/18723 | 4.06e-03 | 2.02e-02 | 68 |
GO:0048814 | Prostate | BPH | regulation of dendrite morphogenesis | 20/3107 | 67/18723 | 4.93e-03 | 2.33e-02 | 20 |
GO:1901890 | Prostate | BPH | positive regulation of cell junction assembly | 28/3107 | 104/18723 | 5.18e-03 | 2.43e-02 | 28 |
GO:00605383 | Prostate | BPH | skeletal muscle organ development | 40/3107 | 166/18723 | 8.09e-03 | 3.52e-02 | 40 |
GO:00467778 | Prostate | BPH | protein autophosphorylation | 52/3107 | 227/18723 | 8.26e-03 | 3.59e-02 | 52 |
GO:00075175 | Prostate | BPH | muscle organ development | 71/3107 | 327/18723 | 9.00e-03 | 3.84e-02 | 71 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EEF2 | SNV | Missense_Mutation | | c.2069N>T | p.Gly690Val | p.G690V | P13639 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD |
EEF2 | SNV | Missense_Mutation | novel | c.1130N>T | p.Pro377Leu | p.P377L | P13639 | protein_coding | tolerated(0.56) | benign(0) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
EEF2 | SNV | Missense_Mutation | | c.615N>G | p.Ile205Met | p.I205M | P13639 | protein_coding | deleterious(0) | benign(0.248) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EEF2 | SNV | Missense_Mutation | | c.358N>G | p.Arg120Gly | p.R120G | P13639 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AR-A24K-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
EEF2 | SNV | Missense_Mutation | rs778994144 | c.688G>A | p.Glu230Lys | p.E230K | P13639 | protein_coding | tolerated(1) | probably_damaging(0.993) | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EEF2 | SNV | Missense_Mutation | novel | c.586N>A | p.Glu196Lys | p.E196K | P13639 | protein_coding | tolerated(0.21) | benign(0.027) | TCGA-C8-A3M7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
EEF2 | SNV | Missense_Mutation | | c.1738N>T | p.Arg580Cys | p.R580C | P13639 | protein_coding | deleterious(0.04) | possibly_damaging(0.869) | TCGA-EW-A1IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD |
EEF2 | insertion | Nonsense_Mutation | novel | c.839_840insTTGCTCTGTTGCTTAGGCTGGAGTGCAATGG | p.Glu281CysfsTer5 | p.E281Cfs*5 | P13639 | protein_coding | | | TCGA-AN-A0FV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EEF2 | SNV | Missense_Mutation | novel | c.31N>A | p.Ala11Thr | p.A11T | P13639 | protein_coding | tolerated(0.32) | benign(0.001) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
EEF2 | SNV | Missense_Mutation | | c.1801N>T | p.Arg601Trp | p.R601W | P13639 | protein_coding | deleterious(0) | probably_damaging(0.936) | TCGA-EA-A3HT-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |